Injectable EMD Protein Composition for Gingival Soft Tissue Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current surgical techniques for soft tissue reconstruction in the craniomaxillofacial complex, such as in the oral cavity, are invasive and carry a high risk of infection and inflammatory complications, with limited success in achieving ideal functional and aesthetic outcomes due to the limited availability of suitable local tissues.
Innovation Solution
A pharmaceutical, dental, and cosmetic composition comprising purified enamel matrix derivative (EMD) proteins with specific molecular weight and particle size, pH, and depleted peak components, optionally with human fibroblasts, administered via injection to promote soft tissue growth and healing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If surgical techniques are used for soft tissue reconstruction, then tissue closure and defect obturation are achieved, but infection risk and inflammatory complications increase
Solution Approach 1:
The patent replaces mechanical surgical intervention with a biochemical approach using EMD compositions. Instead of surgical flaps and grafts that create physical trauma, the invention uses enamel matrix derivative proteins to stimulate natural tissue regeneration, thereby eliminating surgical infection risks while achieving soft tissue reconstruction
Solution Approach 2:
The EMD composition acts as an intermediary substance that mediates between the injury site and the body's natural healing mechanisms. The purified enamel matrix proteins serve as a biological mediator that activates and directs endogenous regenerative processes, avoiding direct surgical contact and associated infection risks
2Reliability
If surgical techniques are used for soft tissue reconstruction, then defect closure is achieved, but tissue trauma increases
Solution Approach 1:
The patent replaces mechanical surgical techniques with a biochemical regenerative approach. Instead of physically moving and suturing tissues which causes trauma, the EMD composition chemically stimulates cells to naturally regenerate and close defects, eliminating surgical trauma while achieving the same clinical outcome
3Quantity of substance
If local regional and distant flap harvests are used, then tissue availability increases, but procedural complexity increases
Solution Approach 1:
The patent extracts and purifies the essential bioactive components (enamel matrix proteins) from their natural source (developing tooth enamel). This extraction process isolates the regenerative factors that can be applied locally without requiring complex flap harvest procedures from multiple body sites, simplifying the overall treatment while maintaining tissue regeneration capability
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to a pharmaceutical, dental and/or cosmetic composition comprising purified and/or isolated matrix derivative (EMD) proteins and a suitable pharmaceutical carrier, characterized in that the purified and/or isolated enamel matrix derivative (EMD) proteins comprised in said composition have a predominant MW of between 10-13kDa and an aggregation particle size of between 20-200 nm at Room Temperature (RT) and a pH of between 6.0-7.5. Said pharmaceutical, dental and/or cosmetic composition is disclosed for use in healing, restoration, enhancement and/or promotion of soft tissue in the oral cavity and/or craniomaxillofacial complex (CMF), in particular for use in treating patients suffering from a gingival deficiency and/or disorder. Preferably, the composition of the invention is administered via injection into the soft tissue in the oral cavity and/or the craniomaxillofacial complex (CMF) of the patient.